共 50 条
- [1] A first-in-human phase 1a dose-escalation study of BGB-15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti-PD-1 antibody) in patients (pts) with advanced solid tumors[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Deva, SanjeevZhou, CaicunBishnoi, Sarwan K.Lau, Peter Kar HanTran, BenBa, YiGalsky, Matt D.Wang, YongshengZhang, YanqiaoLuo, SuxiaChang, VictoriaYu, CunjingZhang, TeresaZhang, HeatherMa, JiafangNaicker, Kirsha MayYap, Timothy A.
- [2] A first-in-human phase I study of CYH33, a phosphatidylinositol 3-kinase (PI3K) α selective inhibitor, in patients with advanced solid tumors.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Wei, Xiao-LiXu, Rui-huaZhao, HongyunZhang, YangZou, Ben-YanWang, FengLiu, JihongWang, ZhiqiangQiu, Miao-ZhenYu, QiuqiongLiu, Yun
- [3] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors[J]. CANCER DISCOVERY, 2017, 7 (07) : 704 - 715Juric, DejanKrop, IanRamanathan, Ramesh K.Wilson, Timothy R.Ware, Joseph A.Bohorquez, Sandra M. SanabriaSavage, Heidi M.Sampath, DeepakSalphati, LaurentLin, Ray S.Jin, HuanParmar, HemaHsu, Jerry Y.Von Hoff, Daniel D.Baselga, Jose
- [4] A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Patnaik, A.Appleman, L. J.Mountz, J. M.Ramanathan, R. K.Beeram, M.Tolcher, A. W.Papadopoulos, K. P.Lotze, M. T.Petro, D. P.Laymon, C.Paige, L.Rajagopalan, P.Jeffers, M.Roth, D.Dubowy, R. L.
- [5] A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies[J]. CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5015 - 5023Juric, Dejande Bono, Johann S.LoRusso, Patricia M.Nemunaitis, JohnHeath, Elisabeth I.Kwak, Eunice L.Macarulla Mercade, TeresaGeuna, Elenade Miguel-Luken, Maria JosePatel, ChiragKuida, KeisukeSankoh, SerapWestin, Eric H.Zohren, FabianShou, YapingTabernero, Josep
- [6] A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)Naing, AungGainor, Justin F.Gelderblom, HansForde, Patrick M.Butler, Marcus O.Lin, Chia-ChiSharma, Sunilde Olza, Maria OchoaVarga, AndreaTaylor, MatthewSchellens, Jan H. M.Wu, HongqianSun, HaiyingSilva, Antonio P.Faris, JasonMataraza, JenniferCameron, ScottBauer, Todd M.
- [7] First-in-human dose-escalation study of the phosphatidylinositol 3-kinase α-selective inhibitor HS-10352 in advanced breast cancer.[J]. CANCER RESEARCH, 2022, 82 (12)Ouyang, QuchangWang, YingZhang, JianWu, QiongSun, ChanganWei, HongyingQian, XiaolingHu, Xichun
- [8] Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Shapiro, G.Kwak, E.Baselga, J.Rodon, J.Scheffold, C.Laird, A. D.Bedell, C.Edelman, G.
- [9] First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors[J]. NATURE COMMUNICATIONS, 2022, 13 (01)Wei, Xiao-LiLiu, Fu-RongLiu, Ji-HongZhao, Hong-YunZhang, YangWang, Zhi-QiangQiu, Miao-ZhenXu, FeiYu, Qiu-QiongDu, Yi-WuShi, Yan-XiaWang, De-ShengWang, Feng-HuaXu, Rui-Hua
- [10] First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors[J]. Nature Communications, 13Xiao-Li WeiFu-Rong LiuJi-Hong LiuHong-Yun ZhaoYang ZhangZhi-Qiang WangMiao-Zhen QiuFei XuQiu-Qiong YuYi-Wu DuYan-Xia ShiDe-Sheng WangFeng-Hua WangRui-Hua Xu